Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw

This study evaluated the risks of developing ONJ when replacing ZA with denosumab.

Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - February 28, 2018 Category: ENT & OMF Authors: Tomoko Higuchi, Yoshihiko Soga, Misato Muro, Makoto Kajizono, Yoshihisa Kitamura, Toshiaki Sendo, Akira Sasaki Tags: Oral Medicine Source Type: research